دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 4,800,000 تومان- قیمت ویژه : 2,400,000تومان
دسترسی ۳ ماهه به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 93 ﺭﻭﺯ
قیمت : 1,500,000 تومان- قیمت ویژه : 750,000تومان
Cancer: another casualty of geopolitical unrest?
doi : 10.1016/S1470-2045(26)00021-5
Volume 27, Issue 2, February 2026, Page 137
Oligometastatic prostate cancer: time to integrate metastasis-directed therapy
Concordant phase 2 evidence and biological plausibility for rare tumours
Sharing patient-reported outcomes with clinical investigators in real time
Media coverage and PATHFINDER2: hype, simplification, and free advertising
Time to act: a global call for oral cancer prevention and early detection
Daratumumab–lenalidomide and the immunosuppressive budget in myeloma
Daratumumab–lenalidomide and the immunosuppressive budget in myeloma – Authors' reply
Factors that can make overall survival unreliable as a clinical trial outcome
Factors that can make overall survival unreliable as a clinical trial outcome – Authors' reply
Ezabenlimab with induction chemotherapy and adaptive chemoradiotherapy in stage 3 squamous cell anal carcinoma
Ezabenlimab with induction chemotherapy and adaptive chemoradiotherapy in stage 3 squamous cell anal carcinoma – Authors' reply
Donated sperm with TP53 mutation used to conceive at least 197 children
Radiotherapy has a role to play in patients with EGFR-mutated non-small-cell lung cancer in first-line treatment
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration
Evaluation of progression-free status at 24 months as a surrogate endpoint for overall survival in patients with human papillomavirus-positive oropharyngeal cancer: a retrospective cohort study
Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial
Estimated effect of correcting inequalities in minimally invasive surgical resection in patients with colon cancer in England: a population-based study
Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial
Inter-rater reliability of CTCAE assessments with or without EORTC patient-reported outcome data in a mixed cancer population: a multinational, open-label, randomised controlled trial
Classification accuracy of a hierarchical molecular inference-based deep-learning system for CNS tumour diagnosis: a multi-institutional, retrospective study
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
The power of words: evaluating the role of qualitative methods in cancer research
Expert recommendations for the conduct and appraisal of qualitative research in oncology
Reirradiation Collaborative Group (ReCOG) consensus on standards for dose evaluation and reporting in patients with multiple courses of radiation therapy: an AAPM/ACRO/ASTRO/CARO/COMP/CADRA/CPQR/ESTRO/NRG-endorsed consensus statement
International Multidisciplinary Consensus Group for Malignant Spinal Cord Compression: recommendations for definitions, reporting items, and study endpoints for clinical trials and audits
